Seres Therapeutics
Open
$5.75
Prev. Close
$5.75
High
$5.75
Low
$5.66
Market Snapshot
$54.64M
-1.2
-0.40
66
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Recently from Cashu
Seres Therapeutics Advances Microbiome Therapies for Infectious Diseases and Personalized Medicine
Seres Therapeutics: Poised at the Microbiome Frontier Seres Therapeutics, a clinical-stage biotechnology firm specializing in microbiome therapeutics, continues to lead the charge in the innovative fi…
Seres Therapeutics Leads Microbiome Innovations with SER-109 for Clostridioides difficile Infection
Seres Therapeutics: Innovations in Microbiome Therapeutics Steer Industry Forward Seres Therapeutics stands at the forefront of microbiome therapeutic advancements, focusing on the development of inno…
Seres Therapeutics Advances Microbiome Science to Revolutionize Treatments for Chronic Health Disorders
Seres Therapeutics Prepares for Key Developments in the Microbiome Sector Seres Therapeutics, a leader in microbiome-based therapeutics, continues to position itself at the forefront of innovative hea…
Seres Therapeutics Pioneers Microbiome Therapies with Promising SER-109 for CDI
Advancements in Microbiome Therapeutics: Seres Therapeutics Leads the Charge Seres Therapeutics is at the forefront of microbiome-based therapeutics, making significant strides in the treatment of var…